News

MassDevice2h
Regeneron to acquire 23andMe for $256M, plans to continue consumer genetics services
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...
Daily Voice on MSN5h
Westchester-Based Regeneron Buying Bankrupt 23andMe For $256M, Pledges To Protect DNA Data
Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, ...
Regeneron Pharmaceuticals (NasdaqGS:REGN) Partners With Viz.ai For AI-Powered COPD Solutions
Viz.ai's recent partnership with Sanofi and Regeneron Pharmaceuticals (NasdaqGS:REGN) brings AI technology to aid in the management of COPD patients, enhancing the healthcare process. Throughout the ...
23andMe sells its most valuable asset to biotech company Regeneron, which promises to keep your DNA private
Regeneron said it will continue uninterrupted service of 23andMe’s consumer genome services after its purchase closes as ...
JD Supra1h
Regeneron Awarded $407 Million in Amgen Antitrust Suit
On May 15, 2025, a jury returned a verdict finding Amgen Inc. (“Amgen”) liable for antitrust violations and awarding Regeneron Pharmaceuticals, ...
Regeneron agrees to buy bankrupt 23andMe, promises ethical use of customers' DNA data
Regeneron Pharmaceuticals said on Monday it will buy genetic testing firm 23andMe Holding for $256 million through a ...
Pharmaceutical Technology3h
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care
All participants will initially undergo a run-in period on standardised medium-dose ICS/LABA to confirm persistent lack of ...
Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD)
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a multi-year ...